Private-Equity Firms Bain and Kohlberg Make Another Big Bet on Biopharma Industry

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading